Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.

TitlePassive immunotherapy of viral infections: 'super-antibodies' enter the fray.
Publication TypeJournal Article
Year of Publication2018
AuthorsWalker LM, Burton DR
JournalNat Rev Immunol
Volume18
Issue5
Pagination297-308
Date Published05/01/2018
ISSN1474-1741
Abstract

Antibodies have been used for more than 100 years in the therapy of infectious diseases, but a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies (sometimes referred to as 'super-antibodies') offers new opportunities for intervention. The isolation of these antibodies, most of which are rarely induced in human infections, has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation. Engineering the antibodies to improve half-life and effector functions has further augmented their in vivo activity in some cases. Super-antibodies offer promise for the prophylaxis and therapy of infections with a range of viruses, including those that are highly antigenically variable and those that are newly emerging or that have pandemic potential. The next few years will be decisive in the realization of the promise of super-antibodies.

DOI10.1038/nri.2017.148
Alternate JournalNat. Rev. Immunol.
PubMed ID29379211
PubMed Central IDPMC5918154
Grant ListUM1 AI100663 / AI / NIAID NIH HHS / United States
CHAVI-ID: 
1
Cover Picture: 
Sal-List: 
1